


Supplementary Figure 1: The plot shows the BIC for the model-based number of classes in the latent class mixed models for DAS28 (A), PGA (B) and PhGA (C).



Supplementary Table 1: Frequencies and percentages of second b/tsDMARD prescription in D2T-patients after failure to first b/tsDMARD.

| | D2T-inefficacy (n=58) | D2T-others (n=30) |
|-----------|-----------------------|-------------------|
| TNFi | 29 (50.0) | 15 (50.0) |
| IL6i | 18 (31.0) | 2 (6.7) |
| Abatacept | 7 (12.1) | 5 (16.6) |
| Rituximab | 3 (5.1) | 5 (16.6) |
| JAKi | 1 (1.8) | 3 (10.0) |

TNFi: Tumor necrosis factor inhibitor; IL6i: interleukin 6 inhibitor; JAKi: Janus Kinase inhibitor.

Supplementary Table 2: Results from mixed-effect logistic regression models between groups.

| Predictor | NoD2TRA Vs D2TRA _{-inefficacy} | | | NoD2TRA Vs D2TRA _{-other} | | |
|-----------|---|-----------|---------|------------------------------------|----------|---------|
| | OR | CI 95% | p-value | OR | CI 95% | p-value |
| DAS28 | 0.7 | 0.2-1.8 | n.s. | 0.9 | 0.2-3.5 | n.s. |
| PGA | 0.99 | 0.9-1.04 | n.s. | 0.98 | 0.9-1.08 | n.s. |
| PhGA | 0.98 | 0.92-1.04 | n.s. | 0.99 | 0.8-1.2 | n.s. |

n.s.: No significance considering a threshold of 0.05

DAS28: Disease activity Score 28; PGA: Patient global assessment; PhGA: Physician global assessment; OR: Odds Ratio; CI: Confidence interval.